This is a non-core endpoint: only basic statistics are computed.
Abnormal findings in cerebrospinal fluid
R18_ABNORMAL_FINDI_CEREBROS_FLUID
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
106 |
4. Check minimum number of eventsNone |
106 |
5. Include endpointsNone |
106 |
6. Filter based on genotype QC (FinnGen only) |
106 |
Control definitions (FinnGen only)
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- R8[3-9]
- Name in latin
- Reperta abnormia in liquore cerebrospinali
Similar endpoints
↥List of similar endpoints to
Abnormal findings in cerebrospinal fluid
based on the number of shared cases.
Similar with more cases:
- Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 106 | 66 | 40 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 47.98 | 46.11 | 51.08 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 91
- Matched controls
- 911
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
R83.8
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Other abnormal findings
+∞
22.9
21
*
R83.4
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Abnormal immunological findings
+∞
21.7
20
*
R83.6
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Abnormal cytological findings
+∞
18.3
17
*
TAB00
NOMESCO Finland
Lumbar puncture
18.8
15.1
23
16
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
9.4
13.0
28
41
R83.9
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Unspecified abnormal finding
+∞
10.6
10
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
9.8
10.4
21
27
R83.0
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Abnormal level of enzymes
+∞
9.5
9
*
R51.80
ICD-10 Finland
Headache
5.4
9.5
31
79
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
98.8
8.6
9
*
R83.2
ICD-10 Finland
Abnormal findings in cerebrospinal fluid, Abnormal level of other drugs, medicaments and biological substances
+∞
8.5
8
*
G35
ICD-10 Finland
Multiple sclerosis
+∞
8.5
8
*
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
+∞
8.5
8
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
7.4
7
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
7.4
7
*
H02AB06
ATC
prednisolone; systemic
3.4
7.2
57
299
ZX120
NOMESCO Finland
Intravenous
6.1
6.8
18
35
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
74.9
6.5
7
*
Z01.8
ICD-10 Finland
Other specified special examinations
3.7
6.5
31
111
R07.4
ICD-10 Finland
Chest pain, unspecified
3.5
6.2
33
128
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
14
10
15.98
15.33
1.9
1.6
—
—
—
0
0
14
18
8.81
10.40
1.2
1.2
—
—
—
0
0
14
18
8.81
10.40
1.2
1.2
—
—
—
0
0
11
10
12.16
10.33
1.2
1.0
—
—
—
0
0
24
56
5.25
10.21
7.3
4.0
1.22
1.23
mmol/l
0.32
24
50
12
15
8.89
9.05
1.2
1.1
—
—
—
0
0
11
13
9.33
8.62
1.7
1.2
—
—
—
0
0
54
257
3.24
8.21
2.3
2.0
109.83
155.01
u/l
0.70
47
244
82
502
3.80
8.15
11.0
10.1
4.39
4.01
e9/l
0.90
72
445
69
382
3.31
8.06
7.8
6.3
1.20
1.22
mmol/l
0.95
57
325
10
12
9.10
7.71
1.3
1.1
—
—
—
0
0
69
393
3.17
7.47
4.1
3.3
0.00
0.00
estimate
0.00
27
79
48
225
3.07
7.31
3.6
2.5
0.59
0.29
e6/l
0.38
38
165
69
396
3.13
7.31
5.3
4.4
0.00
0.00
estimate
0.00
27
76
69
402
3.05
7.01
4.1
3.3
0.00
0.00
estimate
0.00
25
76
11
17
7.10
6.92
3.2
1.2
—
—
—
0
0
22
66
3.94
6.72
3.5
3.0
—
—
—
0
0
57
307
2.85
6.58
4.6
3.4
—
—
—
0
0
76
481
3.05
6.40
6.8
4.2
7.06
6.65
mmol/l
0.57
70
444
31
121
3.21
6.35
3.9
1.8
11.85
14.19
umol/l
0.99
25
104
53
280
2.79
6.27
3.8
2.8
—
—
—
0
0
9
6
16.21
6.02
1.2
1.5
—
—
—
0
0
66
400
2.72
5.82
3.8
2.5
121.92
101.44
ug/l
0.34
60
365
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
9
10.79
5.13
1.1
1.4
—
—
—
0
0
14
37
4.21
5.00
6.1
7.3
25.41
24.92
mmol/l
0.18
14
37
37
186
2.52
4.58
3.0
1.9
3.98
2.81
mg/l
0.95
32
158
8
10
8.54
4.14
3.5
4.6
62.25
55.90
%
—
8
10
6
5
12.60
3.81
1.3
1.8
—
—
—
0
0
6
5
12.60
3.81
1.2
1.0
—
—
—
0
0
38
215
2.20
3.47
5.3
3.7
0.00
0.00
estimate
0.00
27
73
25
118
2.46
3.45
1.6
1.8
—
—
—
0
0
49
308
2.10
3.41
2.0
1.8
99.91
97.21
pmol/l
0.18
24
169
97
824
3.08
3.37
22.6
11.1
87.80
85.13
ml/min/173m2
0.60
88
665
9
19
5.07
3.32
1.2
1.2
—
—
—
0
0
47
295
2.07
3.25
5.3
2.8
43.45
31.43
u/l
0.32
42
278
30
160
2.22
3.13
3.6
3.0
28.93
73.31
ng/l
0.61
24
113
46
290
2.04
3.11
3.4
2.5
2.32
2.37
mmol/l
1.05
38
249
47
299
2.03
3.10
4.7
3.0
47.02
41.31
ng/l
0.07
36
186
5
5
10.40
3.01
1.4
2.0
—
—
—
0
0
5
5
10.40
3.01
1.0
1.4
—
—
—
0
0
5
5
10.40
3.01
1.2
1.6
—
—
—
0
0
5
6
8.66
2.78
1.0
1.2
—
—
—
0
0
12
43
3.02
2.75
1.8
1.3
—
—
—
0
0
6
10
6.28
2.73
1.3
1.0
—
—
—
0
0
32
184
2.06
2.73
1.9
1.7
0.74
0.87
mg/l
0.17
26
146
12
44
2.95
2.65
4.4
2.1
5.21
5.08
kpa
0.21
12
39
100
891
3.16
2.58
24.9
11.6
17.04
20.82
mg/l
0.67
83
688
7
16
4.60
2.52
1.1
1.3
—
—
—
0
0
16
71
2.48
2.49
2.8
2.5
0.21
0.22
g/l
0.10
16
64
29
166
2.03
2.48
1.6
1.8
460.04
450.77
pmol/l
0.05
24
145
10
34
3.14
2.48
1.7
1.8
—
—
—
0
0
82
664
2.04
2.43
5.1
3.9
14.49
14.60
pmol/l
0.12
77
607
30
181
1.92
2.20
1.2
1.2
39.13
32.53
iu/ml
0.10
12
60
16
76
2.30
2.15
1.5
1.6
—
—
—
0
0
29
178
1.87
2.01
1.3
1.3
3.48
9.15
u/ml
0.71
16
71
7
21
3.49
2.00
5.9
1.6
141.00
129.42
g/l
—
7
12
32
203
1.83
2.00
2.4
2.7
886.74
680.58
ng/l
0.25
27
169
16
80
2.18
1.92
1.6
1.7
—
—
—
0
0
7
22
3.33
1.91
1.3
1.2
—
—
—
0
0
89
768
1.99
1.84
30.3
14.1
13.94
13.60
%
0.85
89
759
5
13
3.98
1.73
1.0
1.3
—
—
—
0
0
21
123
1.88
1.66
2.4
2.2
1.41
2.81
e6/l
0.57
11
61
8
32
2.62
1.63
1.1
1.5
—
—
—
0
0
31
207
1.70
1.60
1.4
1.3
0.79
2.05
u/ml
0.66
12
55
5
15
3.44
1.54
1.0
1.1
—
—
—
0
0
9
38
2.49
1.50
1.2
1.4
—
—
—
0
0
28
186
1.69
1.47
2.4
1.6
—
—
—
0
0
9
43
2.19
1.34
6.7
10.0
1.33
1.61
%
—
9
43
9
43
2.19
1.34
6.7
9.9
0.64
0.68
%
—
9
43
23
151
1.67
1.25
1.1
1.2
—
—
—
0
0
8
37
2.25
1.24
1.6
1.7
—
—
—
0
0
21
135
1.69
1.23
2.3
2.1
0.73
0.78
e6/l
0.06
11
74
5
19
2.71
1.23
1.4
2.3
—
—
—
0
0
52
415
1.50
1.22
4.7
4.0
—
—
—
0
0
14
80
1.86
1.20
2.4
1.9
44.43
29.91
u/l
0.62
14
68
5
20
2.57
1.16
1.0
1.1
—
—
—
0
0
10
51
2.06
1.15
2.0
1.6
—
—
—
0
0
0
31
0.00
0.98
0.0
1.5
—
258.31
—
0
18
17
110
1.65
0.98
2.0
1.6
1.59
1.47
%
0.17
11
96
6
27
2.29
0.95
2.2
3.2
—
—
—
0
0
6
28
2.21
0.93
1.0
1.2
—
—
—
0
0
6
28
2.21
0.93
1.0
1.2
—
—
—
0
0
88
803
1.56
0.93
5.5
5.2
40.79
39.01
mmol/mol
0.79
83
754
6
29
2.13
0.91
1.2
1.2
—
—
—
0
0
6
31
1.99
0.86
1.3
1.2
—
2.53
—
0
7
5
97
0.49
0.83
2.2
4.6
28.20
32.47
%
—
5
60
9
53
1.76
0.78
1.0
1.2
—
—
—
0
0
5
28
1.82
0.67
1.4
1.5
—
—
—
0
0
8
51
1.61
0.62
1.0
1.0
—
—
—
0
0
0
20
0.00
0.61
0.0
2.0
—
—
—
0
0
88
823
1.41
0.60
22.1
12.3
39.41
40.60
%
0.58
64
636
28
230
1.30
0.49
1.4
1.7
1.60
1.35
mmol/l
0.59
23
196
89
844
1.34
0.46
4.4
4.2
6.24
5.86
mmol/l
0.53
84
788
89
844
1.34
0.46
4.0
3.8
1.32
1.26
mmol/l
0.32
84
781
5
33
1.54
0.42
2.0
1.9
—
—
—
0
0
5
33
1.54
0.42
2.6
2.5
0.86
1.38
%
—
5
33
66
613
1.20
0.36
4.5
3.2
—
—
—
0
0
10
74
1.39
0.33
2.7
1.7
—
—
—
0
0
6
46
1.32
0.33
3.3
2.4
232.83
95.00
ng/l
—
6
40
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
17
196
0.84
0.21
4.4
3.5
23.36
22.64
%
—
7
74
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
22
196
1.15
0.18
2.3
2.2
—
—
—
0
0
91
890
1.16
0.15
5.0
4.6
2.74
2.83
mmol/l
0.42
86
826
7
84
0.82
0.07
1.4
1.5
—
—
—
0
0
13
142
0.90
0.07
3.8
2.4
1.15
0.73
ug/l
—
8
86
24
230
1.06
0.04
3.9
4.0
18.97
16.44
mg/mmol
0.06
15
138
13
122
1.07
0.03
4.9
1.7
—
—
—
0
0
11
103
1.08
0.02
1.6
1.6
—
—
—
0
0
14
137
1.03
0.00
5.8
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: R18_ABNORMAL_FINDI_CEREBROS_FLUID – Abnormal findings in cerebrospinal fluid
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).